Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients
Kidney and Dialysis · 13.08.2026 · 6 (3) · 56
DOI: 10.3390/kidneydial6030056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney and Dialysis, online erschienen am 13.08.2026. Verfasst von Hao Thi Minh Dinh und 2 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cardiovascular complications majorly drive mortality across the spectrum of chronic kidney disease (CKD). This study evaluated serum Galectin-3 levels across chronic kidney disease (CKD) stages and their association with microinflammation and cardiac dysfunction in MHD patients.
Methods
This cross-sectional study included 206 patients (CKD stages 3–5 non-dialysis [ND], MHD, and post-kidney transplantation) and 70 healthy controls. Serum Galectin-3 was measured using a Chemiluminescent Microparticle Immunoassay.
Results
Median Galectin-3 levels increased progressively from stage 3 (29.50 ng/mL) to stage 4 (39.85 ng/mL), reached the highest levels in stage 5ND (52.70 ng/mL) and MHD (65.15 ng/mL), but plunged post-transplantation (19.45 ng/mL). In the MHD group, patients with high Galectin-3 (>65.15 ng/mL) exhibited significantly higher CRP levels compared to those with low Galectin-3 (2.39 vs. 1.22 mg/L, p = 0.013). Galectin-3 correlated positively with troponin T (r = 0.266, p = 0.037). ROC analysis showed that Galectin-3 discriminated left ventricular systolic dysfunction (EF < 50%) with an AUC of 0.557 (95% CI: 0.401–0.714), yielding an optimal cut-off of ≥52.85 ng/mL (sensitivity: 86.7%, specificity: 31.9%).
Conclusions
Serum Galectin-3 is elevated in MHD patients and correlates with systemic microinflammation (CRP), but its association with myocardial injury lost statistical significance after multivariable adjustment (p = 0.057). Furthermore, an exploratory cut-off of ≥52.85 ng/mL did not demonstrate statistically significant discrimination for left ventricular systolic dysfunction (p = 0.506), highlighting the complex, multifactorial nature of uremic cardiomyopathy.
Zitieren
APA
Dinh, H. T. M., Ton, N. T., & Vo, T. (2026). Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients. Kidney and Dialysis, 6(3), 56. https://doi.org/10.3390/kidneydial6030056
Vancouver
Dinh HTM, Ton NT, Vo T. Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients. Kidney and Dialysis. 2026;6(3):56. doi:10.3390/kidneydial6030056
BibTeX
@article{Dinh2026,
author = {Dinh, Hao Thi Minh and Ton, Ngoc That and Vo, Tam},
title = {Evaluation of Serum Galectin-3 Levels Across Chronic Kidney Disease Stages and Its Association with Cardiovascular Complications in Maintenance Hemodialysis Patients},
journal = {Kidney and Dialysis},
year = {2026},
volume = {6},
number = {3},
pages = {56},
doi = {10.3390/kidneydial6030056}
}
EUVIMED